Loading page

WholenessCommunity

Shop Learn Community Resources

Find a Provider Sell on WholenessLog in

Preparing your space

WholenessCommunity

A dedicated home where people navigating acute and chronic medical conditions find community, independent providers, and genuine support throughout their journey.

Support hours: Mon–Fri, 9:00 AM – 5:00 PM EST

Join the Community

Explore

Shop
Learn
Community
Resources

Providers

Find a Provider
Sell on Wholeness
Provider Onboarding

Support

Returns & Refunds
About Us
Contact Us
Case Studies

Join our wellness community

Weekly inspiration, provider spotlights and healing resources.

© 2026 WCM LLC, d/b/a Wholeness Community Marketplace. All rights reserved.

Privacy Policy Member Terms Provider Terms Returns & Refunds

Conditions & Recovery · Cancer Health Magazine · September 10, 2026

Targeting CDK2 Could Boost Immunotherapy Response in Patients With a Wide Range of Cancers

CDK2 is a protein that controls cell growth and division and a potential target for overcoming resistance to immune checkpoint inhibitors.

Originally published by Cancer Health Magazine. We curate and add context; they did the reporting.

Read the full story at Cancer Health Magazine ↗

Related learning

Biotech Firm Claims Some Credit for Groundbreaking Virus Research Biotech Firm Claims Some Credit for Groundbreaking Virus Research James P. Allison, Ph.D., bangs gong after completing proton therapy treatment Combination therapy helps plasmacytoid bladder cancer survivor